公开(公告)号：EP1683794A1

公开(公告)日：2006-07-26

申请号：EP06005248.7

申请日：2004-10-29

申请人： Arena Pharmaceuticals, Inc. ,  Merck and Co., Inc.

发明人： Semple, Graeme ,  Schrader, Thomas ,  Skinner, Philip, J. ,  Colletti, Steven, L. ,  Gharbaoui, Tawfik ,  Imbriglio, Jason, E. ,  Jung, Jae-Kyu ,  Liang, Rui ,  Raghavan, Subharekha ,  Schmidt, Darby ,  Tata, James, R.

IPC分类号： C07D403/04 ,  C07D495/04 ,  C07D491/04 ,  A61K31/41

CPC分类号： C07D491/04 ,  C07D403/04 ,  C07D495/04

摘要： The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

摘要翻译： 本发明涉及式（I）的某些四唑衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病（包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病）的方法 ，综合征-X等。 此外，本发明还提供本发明化合物与其它活性剂如属于类葡糖苷酶抑制剂，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成 抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂等。